Zaloguj Zarejestruj się zadarmo

Last updated: 4 March 2020 at 7:47pm EST

David McMullin Net Worth




The estimated Net Worth of David Mc Mullin is at least $1.62 Milion dollars as of 5 September 2019. Mr. Mullin owns over 4,329 units of Aldeyra Therapeutics Inc stock worth over $38,056 and over the last 6 years he sold ALDX stock worth over $0. In addition, he makes $1,584,440 as Chief Commercial Officer at Aldeyra Therapeutics Inc.

Mr. McMullin ALDX stock SEC Form 4 insiders trading

David has made over 1 trades of the Aldeyra Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 4,329 units of ALDX stock worth $20,260 on 5 September 2019.

The largest trade he's ever made was buying 4,329 units of Aldeyra Therapeutics Inc stock on 5 September 2019 worth over $20,260. On average, David trades about 1,443 units every 0 days since 2019. As of 5 September 2019 he still owns at least 6,148 units of Aldeyra Therapeutics Inc stock.

You can see the complete history of Mr. Mullin stock trades at the bottom of the page.





David McMullin biography

David McMullin serves as Chief Commercial Officer of the Company. Mr. McMullin joined Aldeyra in 2018 as SVP Corporate Development and Strategy. Mr. McMullin has more than 20 years of biopharmaceutical industry experience, focused on commercialization, business development, and strategic planning operations. Since September 2017, Mr. McMullin has been an advisor on business development to nference, an artificial intelligence start-up synthesizing biomedical knowledge to deliver cutting-edge insights. Mr. McMullin was an executive at Shire plc from 2015 to 2017, as Group Vice President and Head of US Internal Medicine, a $1.4 billion commercial business, from March 2016 until May 2017, and running global commercial operations as VP and Head of Global Commercial Center of Excellence from March 2015 until March 2016. Mr. McMullin was a member of Shire’s In-Line Committee, the executive governing body responsible for commercial performance and execution worldwide, from March 2015 until March 2016. Prior to his work at Shire, Mr. McMullin was VP and Global Head of Supply Chain Operations and Strategy at Novartis Vaccines and Diagnostics from September 2010 until March 2015. Mr. McMullin led an operational turn-around of the supply chain, culminating with the successful acquisition of the business by GlaxoSmithKline plc and CSL Limited in 2015. Mr. McMullin held corporate, sales, marketing and operational roles of increasing responsibility at Novartis from 2003 until 2015, and was the Assistant to the Chairman and CEO of Novartis AG from 2003 until 2005. Before joining Novartis, Mr. McMullin worked at Charles River Associates, Inc. as a business strategy consultant. Mr. McMullin was awarded an M.B.A. with Baker Scholar distinction from Harvard Business School in 2003, and received both a B.A. in Food Science and a B.S. in Economics from Brigham Young University in 1999.

What is the salary of David McMullin?

As the Chief Commercial Officer of Aldeyra Therapeutics Inc, the total compensation of David McMullin at Aldeyra Therapeutics Inc is $1,584,440. There are 2 executives at Aldeyra Therapeutics Inc getting paid more, with Todd Brady having the highest compensation of $4,141,260.



How old is David McMullin?

David McMullin is 45, he's been the Chief Commercial Officer of Aldeyra Therapeutics Inc since 2019. There are 12 older and 2 younger executives at Aldeyra Therapeutics Inc. The oldest executive at Aldeyra Therapeutics Inc is Jesse Treu, 73, who is the Independent Director.

What's David McMullin's mailing address?

David's mailing address filed with the SEC is C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, LEXINGTON, MA, 02421.

Insiders trading at Aldeyra Therapeutics Inc

Over the last 11 years, insiders at Aldeyra Therapeutics Inc have traded over $6,285,725 worth of Aldeyra Therapeutics Inc stock and bought 11,547,153 units worth $75,179,936 . The most active insiders traders include Advisors Llcperceptive Life..., & Johnson Johnson & Johnson... oraz Advisors Llcedelman Josephp.... On average, Aldeyra Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $1,358,662. The most recent stock trade was executed by Stephen Machatha on 12 August 2024, trading 16,041 units of ALDX stock currently worth $76,034.



What does Aldeyra Therapeutics Inc do?

dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise



What does Aldeyra Therapeutics Inc's logo look like?

Aldeyra Therapeutics Inc logo

Complete history of Mr. Mullin stock trades at Aldeyra Therapeutics Inc

Data
#
Firma
 Osoba
Trans.
Transakcja
 Ilość akcji Cena za akcję Łączna cena Ilość akcji po Źródło
5 Sep 2019 ALDX Aldeyra Therapeutics Inc David Mc Mullin
Chief Commercial Officer
 Kupować 4,329 $4.68 $20,260
5 Sep 2019
6,148 ↗


Aldeyra Therapeutics Inc executives and stock owners

Aldeyra Therapeutics Inc executives and other stock owners filed with the SEC include: